Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14101 - 14125 of 14585 in total

5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID

Experimental

Carmegliptin

Carmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.
Investigational

5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione

Experimental

(1R)-2-PHENYLACETAMIDO-2-(3-CARBOXYPHENYL)ETHYL BORONIC ACID

Experimental

2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL

Experimental

BMS-903452

BMS-903452 has been used in trials studying the treatment of Diabetes.
Investigational

Imiglitazar

Imiglitazar has been used in trials studying the treatment of Diabetes Mellitus.
Investigational

E-6005

E6005 has been used in trials studying the treatment of Atopic Dermatitis.
Investigational

MRX-I

MRX-I has been used in trials studying the treatment of Bacterial Infections.
Investigational

NLX-P101

NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
Matched Description: … product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and …

CTS-21166

CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and …

Ivarmacitinib

Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Description: … graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcerative colitis,[L40614] alopecia areata,[L40624] and …

Haloxazolam

Experimental
Illicit

(1S)-1-C-{(2R)-6-[(2R)-2-Butanyl]-5,10-dihydroxy-4-oxo-1,2,3,4-tetrahydro-2-anthracenyl}-5-deoxy-1-O-methyl-D-xylulose

Experimental

3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid

Experimental

5-(4-CYANOPHENYL)-3-{[(2-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID

Experimental

(4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE

Experimental

2-((3'-TERTBUTYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID

Experimental

4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE

Experimental

2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE

Experimental

Mosapramine

Experimental

Indole Naphthyridinone

Experimental

6-Methylamino-5-Nitroisocytosine

Experimental

2-((3'-METHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID

Experimental

Apratastat

Tmi 005 is under investigation in clinical trial NCT00095342 (Study Evaluating TMI-005 in Active Rheumatoid Arthritis).
Investigational
Displaying drugs 14101 - 14125 of 14585 in total